← Eichor
Condition: Rare Malignant Neoplasm Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Rare Malignant Neoplasm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225An International Study on Pediatric Patients With Rare Tumors.
Phase N/A · 1 location(s) · Azienda Ospedaliera di Padova · NCT07072143DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With H
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770102Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2 · 26 location(s) · Teligene US · NCT05168566International Rare Brain Tumor Registry
Phase N/A · 10 location(s) · Children's National Research Institute · NCT05697874Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT07524114Evaluation of Rare and Complex Tumours of the Thoraco-Abdominal and Soft Tissue District
Phase N/A · 2 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06872853International Rare Histiocytic Disorders Registry (IRHDR)
Phase N/A · 15 location(s) · The Hospital for Sick Children · NCT02285582DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cance
Phase 2/Phase 3 · 16 location(s) · Cancer Research UK · NCT05768178TCF-001 TRACK (Target Rare Cancer Knowledge) Study
NA · 1 location(s) · TargetCancer Foundation · NCT04504604Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the
NA · 20 location(s) · Institut Claudius Regaud · NCT03967834Safety and Durability of Sirolimus for Treatment of LAM
Phase N/A · 20 location(s) · University of Cincinnati · NCT02432560DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Phase 2/Phase 3 · 17 location(s) · Cancer Research UK · NCT06988475Ivonescimab in the Treatment of Multiple Advanced Tumors
Phase 2 · 1 location(s) · Fudan University · NCT06683846Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Phase N/A · 3 location(s) · National Cancer Institute (NCI) · NCT03739827The Sarcoma Biology and Outcome Project
Phase N/A · 1 location(s) · Prof. Dr. Richard F Schlenk · NCT04758325SIMPLIFication of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence
NA · 2 location(s) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · NCT06878469Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931Precision Cancer Therapy in Rare Cancers
Phase 2 · 1 location(s) · Oslo University Hospital · NCT06119789DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adul
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05786716Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia
Phase N/A · 18 location(s) · National Cancer Center, Japan · NCT05217407DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Canc
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770037Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced
Phase 2/Phase 3 · 18 location(s) · TuHURA Biosciences, Inc. · NCT06947928Genomic Investigation of Unusual Responders
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT03740503DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusio
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770544CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
Phase N/A · 27 location(s) · University Health Network, Toronto · NCT04151342European Rare Blood Disorders Platform (ENROL)
Phase N/A · 1 location(s) · Hospital Universitari Vall d'Hebron Research Institute · NCT06250595Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo
Phase 2 · 582 location(s) · National Cancer Institute (NCI) · NCT03866382DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05722886Solving Riddles Through Sequencing
Phase N/A · 1 location(s) · Munich Leukemia Laboratory · NCT05046444
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.